Compare Nuwellis Inc (NUWE) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Under Armour Inc Class A — how do they compare? Nuwellis Inc trades at $1.41 (market cap $542.80K), while Under Armour Inc Class A trades at $5.13 (market cap $2.26B). The key difference: Under Armour Inc Class A is far larger — about 4163.6× Nuwellis Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | UA | |
|---|---|---|
Market Cap | $542.80K | $2.26B |
Sector | Technology | Consumer Cyclical |
52-Week High | $220.50 | $7.88 |
52-Week Low | $1.42 | $3.96 |
Enterprise Value | -$1.27M | $3.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.43, up 0.7% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of -$17.52M in 2025, with a negative net income margin of -217.22%, though recent news highlights product development and revenue growth initiatives, including a 14% preliminary year-over-year revenue increase in Q2 2026.
Outlook is cautious due to persistent losses and high cash burn, but growth in pediatric installations and strategic expansions offer potential. Risks include financial sustainability and competitive pressures, while analyst coverage is limited with a split buy/hold consensus.
Under Armour (UA) trades at $5.14, down 9.43% amid bearish technical signals and negative profitability metrics. The company reported Q1 2026 revenue of $1.1 billion, missing expectations, and lowered its fiscal 2027 revenue outlook due to soft consumer demand in North America and Asia-Pacific. Despite beating EPS estimates in two of the last three quarters, negative net income margin of -9.99% and declining revenue trends highlight ongoing challenges.
The stock faces significant headwinds from deteriorating fundamentals and negative cash flow, though analyst consensus remains cautiously optimistic with 38.8% buy ratings. Key risks include continued revenue declines, competitive pressure, and execution challenges in the turnaround strategy. The current valuation at 0.45 P/S offers potential value if management can stabilize operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
